Critical limb ischemia: cell and molecular therapies for limb salvage.

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

There is a growing interest in developing new limb salvage therapies for patients with severe peripheral artery disease who have no alternative to amputation. Cell and gene therapy studies are showing promise in controlling pain and minor ulceration in patients with significant critical limb ischemia. Among cardiovascular cell and molecular therapy programs, The Methodist Hospital is one of the leading centers in both gene and cell therapy for critical limb ischemia. Randomized controlled trials continue to be performed, and these experimental therapies will move from research to pharmacy within the decade. In conjunction with aggressive medical and surgical management, these emergent therapies may help patients with critical limb ischemia avoid a major amputation and are one of the foundations of any advanced limb salvage program.

Original languageEnglish (US)
Pages (from-to)20-27
Number of pages8
JournalUnknown Journal
Volume8
Issue number4
DOIs
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Critical limb ischemia: cell and molecular therapies for limb salvage.'. Together they form a unique fingerprint.

  • Cite this